Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TENAYA phase 3 trial of faricimab versus aflibercept in neovascular age-related macular degeneration
NL-OMON49876Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- Oct 2019
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in exudative macular degeneration comparing Faricimab with Aflibercept active comparator (2 arms). Primary endpoint: Change from baseline in best-corrected visual acuity. Started Oct 2019; status: active, not recruiting.
02
Drugs
faricimabaflibercept
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NL-OMON49876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49876.